Sensus Healthcare, a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions with superficial radiation therapy (SRT), has announced that it will sponsor the First International Keloid Symposium to be held at The Rockefeller University in New York on September 8 and 9.
The event will bring together industry doctors and scientists in order to provide a collaborative environment regarding better practices in the diagnosis, prevention and treatment of keloid disease. Registered attendees include experts in basic science, dermatopathology, specialist clinicians with an interest in keloid scars from dermatology, plastic surgery, oncology, pediatric and general surgery, ENT, maxillofacial as well as specialist nurses, physiotherapists, occupational therapists and psychologists.
The Symposium will also display products, services and devices (existing or in development). It will emphasize scientific and clinical content, highlighting pros and cons of current and newly emerging treatment approaches including surgical management, cryotherapy, electrotherapy, chemotherapy and other interventions.
“We are thrilled to be the platinum sponsor of the First International Keloid Symposium being held at The Rockefeller University in New York City,” said Joe Sardano, CEO of Sensus Healthcare. “Keloid disease is an underserved market which we have a keen interest in helping to address with our SRT devices. It is exciting to display our innovative technology in a unique environment of international thought leaders and practitioners in the industry.”
For more information and registration, visit www.keloidsymposium.com.
